



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Glucagon Receptor Antagonist I

Item No. 21223

CAS Registry No.: 438618-32-7
Formal Name: N-[3-cyano-6-(1,1-dimethylpropyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]-2-ethyl-butanamide
Synonym: GCGR Antagonist I
MF: C₂₀H₃₀N₂OS
FW: 346.5
Purity: ≥99%
UV/Vis.: λ_{max}: 216, 252, 260, 304 nm
Supplied as: A crystalline solid
Storage: -80°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Glucagon receptor antagonist I is supplied as a crystalline solid. A stock solution may be made by dissolving the glucagon receptor antagonist I in the solvent of choice, which should be purged with an inert gas. Glucagon receptor antagonist I is soluble in DMSO.

Description

Glucagon receptor antagonist I is a competitive antagonist of the glucagon receptor (GCGR; IC₅₀ = 181 nM).¹ It blocks glucagon-induced glycogenolysis in primary human hepatocytes and isolated liver.¹ Glucagon receptor antagonist I, at 50 mg/kg, reduces the increase in glucose levels observed after intraperitoneal administration of glucagon in humanized mice.¹ Glucagon receptor antagonist inactive control (Item No. 21188) does not prevent glucagon-mediated actions.¹

Reference

1. Qureshi, S.A., Candelore, M.R., Xie, D., *et al.* A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. *Diabetes* **53(12)**, 3267-3273 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/27/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM